VolitionRx Limited is a clinical-stage life sciences company centered on a straightforward concept: using a standard blood sample to detect and track serious diseases. The firm develops diagnostic tests rooted in Nucleosomics, which focuses on identifying and measuring nucleosomes—basic units of DNA in the bloodstream and other fluids—as signs that disease may be present. Investors track VNRX because the company targets major unmet needs in cancer and sepsis diagnostics with tests positioned as simple, affordable, and straightforward to implement.
VolitionRx Limited was established in 1998 and is based in Henderson, Nevada, with research, production, and commercial activities across Belgium, the United Kingdom, the United States, and Singapore. It is led by President and Group Chief Executive Officer Cameron Reynolds, who also founded the company. VNRX trades on the NYSE American exchange.
The core technology rests on the Nu.Q platform, which identifies and quantifies nucleosomes in blood samples. This supports a range of product areas:
The business approach emphasizes commercialization through direct efforts and licensing and distribution partnerships. Rather than constructing extensive sales and lab infrastructure independently, the company works with larger diagnostic and animal-health firms. Revenue comes mainly from product sales, services, and potential milestone or licensing payments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The financial picture remains that of an early-stage developer, with relatively modest revenue against ongoing operating expenses.
Attention centers on the sizable addressable markets and the platform-based approach to diagnostics. Cancer and sepsis rank among leading global causes of death, and the company views its technology as a low-cost, accessible option for earlier detection. It points to multi-billion-dollar total addressable markets spanning its product areas, from companion-animal screening to human liquid biopsy and multi-cancer early detection.
A central part of the thesis is the adaptability of the Nu.Q platform. One underlying technology applies across veterinary health, sepsis monitoring, and oncology, allowing research to support multiple commercial paths. The licensing strategy supports market reach by teaming with established diagnostic and liquid-biopsy partners that already maintain labs, analyzers, and sales networks, helping avoid the full burden of commercialization costs.
Reported progress includes CE-marked availability of the Nu.Q NETs test in Europe and government-supported clinical programs for sepsis detection. Ongoing work to obtain reimbursement for cancer tests in European markets adds to the longer-term drivers under review.
Investing in VolitionRx involves notable risks common to early-stage life sciences firms. The company has posted ongoing net losses and an accumulated deficit, and its auditors have issued a going-concern opinion highlighting substantial doubt about continuing operations without additional capital. This underscores reliance on further financing, licensing arrangements, or grants to support research, trials, and commercialization.
Additional factors include:
VolitionRx Limited stands out as an epigenetics company working to introduce straightforward blood-based diagnostics for major medical challenges such as cancer and sepsis. Its Nu.Q platform and partnership-focused model provide a distinct path into markets with meaningful long-term potential. At the same time, the company is still early in commercialization, with modest revenue, continued losses, and notable capital needs. For investors, VNRX offers a high-risk, high-uncertainty position in the diagnostics and liquid-biopsy space, best viewed as a speculative holding rather than a mature, cash-generating business.
In my research process, I occasionally use Tickeron’s AI Screener to scan for stocks that align with specific technical, fundamental, or industry criteria. It allows efficient comparison across thousands of names using customizable filters and AI signals, which can help surface ideas that fit a given strategy without reviewing each company individually.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VNRX's RSI Indicator exited the oversold zone, 23 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 46 cases where VNRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In 90 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
VNRX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VNRX broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a development stage life sciences company
Industry MedicalNursingServices